drug · small molecule
remimazolam besylate
Marketedupdated 3mo agoby Acacia Pharma Group Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval, with an approval for sedation.
targets
GABA-A receptor; anion channel
all catalysts(0)
nothing on the calendar yet
Trials studying remimazolam besylate
- phase2Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
- phase3Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
- phase2PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 10, 2027
333 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Jan 13, 2034method-of-use (U-2968)US 9827251
- Apr 30, 2033method-of-use (U-2968)US 9561236
- Nov 7, 2031method-of-use (U-2968)US 10052334
- Nov 7, 2031method-of-use (U-2968)US 10195210
- Nov 7, 2031method-of-use (U-2968)US 10342800
- Nov 7, 2031method-of-use (U-2968)US 10722522
- Nov 7, 2031method-of-use (U-2968)US 9737547
- Jul 10, 2027method-of-use (U-2968)US 10472365333d
- Jul 10, 2027formulationUS 10961250333d
- Jul 10, 2027formulationUS 9777007333d
- Jul 10, 2027formulationUS 9914738333d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that